VR Logo

Chinook Therapeutics Inc. (KDNY) download report


Healthcare | Biotechnology & Pharma Research

Chinook Therapeutics Inc. (KDNY) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases.

IPO Date: 15-Apr-2015

Pres, CEO & Director: Mr. Eric L. Dobmeier J.D.

Chief Operating Officer: Mr. Tom Frohlich

Listing: NASDAQ: KDNY

Country: United States

Headquarters: Seattle, WA

Website: https://www.chinooktx.com

Key Facts

Market cap: $1,078.72 Mln

Revenue (TTM): $2.36 Mln

Earnings (TTM): $-97.41 Mln

Cash: $276.10 Mln

Total Debt: $43.04 Mln

Insider's Holding: 1.27%

Liquidity: Low

52 Week range: $10.48 - 19.57

Shares outstanding: 61,605,800

Stock Performance

Time Period Chinook Therapeutics (KDNY) S&P BSE Sensex* S&P Small-Cap 600*
YTD7.36-8.62-18.78
1 month13.55-4.54-8.00
3 months7.03-10.19-13.65
1 Year24.011.43-17.19
3 Years31.5010.146.10
5 Years-21.0311.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Chinook Therapeutics (KDNY) S&P Small-Cap 600 S&P BSE Sensex
20212.8425.2721.99
2020168.819.5715.75
2019-55.3020.8614.38
2018-64.60-9.705.87
2017-34.2111.7327.91
2016-59.4924.741.95